Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Completed · Phase 3 · Has a placebo group
Conditions studied: Idiopathic Pulmonary Fibrosis
In brief
The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 milligrams per day (mg/d) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to assess the safety and efficacy of treatment with pirfenidone 1197 mg/d in patients with idiopathic pulmonary fibrosis and to characterize the pharmacokinetic disposition of pirfenidone in patients with idiopathic pulmonary fibrosis.
Key facts
- Study ID
- NCT00287716
- Run by
- Genentech, Inc.
- People needed
- 435
- Starts
- 2006-07-14
- Expected to finish
- 2008-11-10
- Last updated by the study team
- 2017-05-22
Who can join
Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- InterMune, Inc. — Brisbane, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.